Inovio Pharmaceuticals (INO) Stock Forecast, Price Target & Predictions
INO Stock Forecast
Inovio Pharmaceuticals stock forecast is as follows: an average price target of $22.67 (represents a 232.89% upside from INO’s last price of $6.81) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
INO Price Target
The average price target for Inovio Pharmaceuticals (INO) is $22.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $8.00. This represents a potential 232.89% upside from INO's last price of $6.81.
INO Analyst Ratings
According to 4 Wall Street analysts, Inovio Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for INO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Inovio Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 09, 2024 | Gregory Renza | RBC Capital | $8.00 | $8.71 | -8.15% | 17.47% |
| May 14, 2024 | Hartaj Singh | Oppenheimer | $40.00 | $11.45 | 249.50% | 487.37% |
| May 13, 2024 | Sudan Loganathan | Stephens | $20.00 | $11.36 | 76.06% | 193.69% |
| Jan 25, 2024 | Hartaj Singh | Oppenheimer | $4.00 | $6.79 | -41.09% | -41.26% |
The latest Inovio Pharmaceuticals stock forecast, released on Aug 09, 2024 by Gregory Renza from RBC Capital, set a price target of $8.00, which represents a -8.15% decrease from the stock price at the time of the forecast ($8.71), and a 17.47% increase from INO last price ($6.81).
Inovio Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $8.00 | $18.00 |
| Last Closing Price | $6.81 | $6.81 | $6.81 |
| Upside/Downside | -100.00% | 17.47% | 164.32% |
In the current month, the average price target of Inovio Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Inovio Pharmaceuticals's last price of $6.81. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| May 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 14, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| May 13, 2024 | Stephens | - | Overweight | Initialise |
| Jan 25, 2024 | Oppenheimer | - | Outperform | Upgrade |
Inovio Pharmaceuticals's last stock rating was published by RBC Capital on Aug 09, 2024. The company gave INO a "Sector Perform" rating, the same as its previous rate.
Inovio Pharmaceuticals Financial Forecast
Inovio Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $388.45M | - | $114.94K | $124.67K | $9.15M | - | $199.07K | $839.12K | $291.70K | $272.82K | $371.12K | $5.58M | $236.18K | $267.19K | $1.33M | $279.49K | $866.86K | $135.67K | $2.83M | $2.00M | $24.45M |
| Avg Forecast | $100.00K | $100.00K | $100.00K | $100.00K | $129.53K | $112.83K | $134.00K | $158.33K | $360.00K | $116.67K | $275.00K | $275.00K | $339.28K | $623.17K | $529.00K | $773.00K | $2.52M | $873.60K | $1.09M | $1.06M | $1.22M | $3.05M | $2.61M | $1.91M | $2.17M | $3.93M | $4.02M | $6.41M | $2.22M | $76.84M |
| High Forecast | $100.00K | $100.00K | $100.00K | $100.00K | $129.53K | $169.25K | $134.00K | $158.33K | $373.85K | $116.67K | $275.00K | $275.00K | $339.28K | $623.17K | $529.00K | $920.24K | $3.00M | $1.04M | $1.30M | $1.26M | $1.45M | $3.63M | $3.10M | $2.28M | $2.59M | $4.68M | $4.79M | $7.63M | $2.67M | $92.21M |
| Low Forecast | $100.00K | $100.00K | $100.00K | $100.00K | $129.53K | $56.42K | $134.00K | $158.33K | $346.15K | $116.67K | $275.00K | $275.00K | $339.28K | $623.17K | $529.00K | $552.14K | $1.80M | $624.00K | $779.14K | $757.68K | $871.46K | $2.18M | $1.86M | $1.37M | $1.55M | $2.81M | $2.87M | $4.58M | $1.78M | $61.47M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 | 19 |
| Surprise % | - | - | - | - | - | - | - | - | - | 3329.53% | - | 0.42% | 0.37% | 14.69% | - | 0.26% | 0.33% | 0.33% | 0.25% | 0.35% | 4.57% | 0.08% | 0.10% | 0.69% | 0.13% | 0.22% | 0.03% | 0.44% | 0.90% | 0.32% |
Inovio Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $360.00K, with a low forecast of $346.15K, and a high forecast of $373.85K. INO's average Quarter revenue forecast represents a -99.91% decrease compared to the company's last Quarter revenue of $388.45M (Sep 23).
Inovio Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 | 19 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-35.55B | - | $-43.55M | $-56.94M | $-34.28M | - | $-70.38M | $-102.17M | $-58.38M | $-80.98M | $-51.81M | $-26.20M | $-7.77M | $-31.36M | $-10.84M | $-29.28M | $-23.66M | $-23.44M | $-27.34M | $-25.68M | $-4.21M |
| Avg Forecast | $-100.00K | $-100.00K | $-100.00K | $-100.00K | $-129.53K | $-112.83K | $-134.00K | $-158.33K | $-360.00K | $-116.67K | $-275.00K | $-275.00K | $-339.28K | $-61.68M | $-529.00K | $-72.83M | $-2.52M | $-65.96M | $-39.13M | $-29.20M | $-1.22M | $-3.05M | $-324.76M | $-23.33M | $-2.17M | $-23.22M | $-20.67M | $-23.76M | $-26.20M | $-8.15M |
| High Forecast | $-100.00K | $-100.00K | $-100.00K | $-100.00K | $-129.53K | $-56.42K | $-134.00K | $-158.33K | $-346.15K | $-116.67K | $-275.00K | $-275.00K | $-339.28K | $-49.34M | $-529.00K | $-58.27M | $-1.80M | $-52.77M | $-31.30M | $-23.36M | $-871.46K | $-2.18M | $-259.81M | $-18.67M | $-1.55M | $-18.58M | $-16.53M | $-19.01M | $-20.96M | $-6.52M |
| Low Forecast | $-100.00K | $-100.00K | $-100.00K | $-100.00K | $-129.53K | $-169.25K | $-134.00K | $-158.33K | $-373.85K | $-116.67K | $-275.00K | $-275.00K | $-339.28K | $-74.01M | $-529.00K | $-87.40M | $-3.00M | $-79.16M | $-46.95M | $-35.04M | $-1.45M | $-3.63M | $-389.72M | $-28.00M | $-2.59M | $-27.87M | $-24.80M | $-28.52M | $-31.45M | $-9.78M |
| Surprise % | - | - | - | - | - | - | - | - | - | 304739.23% | - | 158.38% | 167.84% | 0.56% | - | 0.97% | 40.52% | 0.88% | 2.07% | 1.77% | 21.47% | 2.55% | 0.10% | 0.46% | 13.46% | 1.02% | 1.13% | 1.15% | 0.98% | 0.52% |
undefined analysts predict INO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Inovio Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Inovio Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 | 19 |
| Net Income | - | - | - | - | - | - | - | - | - | $-33.93B | - | $2.95B | $-51.67M | $-39.62M | - | $-83.91M | $-109.00M | $-60.62M | $-82.00M | $-55.25M | $-17.59M | $19.17M | $-128.70M | $-32.54M | $-38.15M | $-22.24M | $-29.58M | $-29.29M | $-25.02M | $-6.64M |
| Avg Forecast | $-22.30M | $-23.66M | $-25.84M | $-28.83M | $-28.29M | $-31.10M | $-29.96M | $-27.56M | $-32.26M | $-41.34M | $-47.32M | $-47.32M | $-54.83M | $-63.08M | $-86.64M | $-74.42M | $-86.31M | $-67.46M | $-39.76M | $-29.92M | $-58.46M | $44.50M | $-333.87M | $-26.62M | $-64.47M | $-23.98M | $-26.12M | $-24.72M | $-27.52M | $-10.05M |
| High Forecast | $-22.30M | $-23.66M | $-25.84M | $-28.83M | $-28.29M | $-29.02M | $-29.96M | $-27.56M | $-26.95M | $-41.34M | $-47.32M | $-47.32M | $-54.83M | $-50.46M | $-86.64M | $-59.54M | $-54.25M | $-53.97M | $-31.80M | $-23.94M | $-36.75M | $53.40M | $-267.10M | $-21.30M | $-40.53M | $-19.18M | $-20.90M | $-19.78M | $-22.01M | $-8.04M |
| Low Forecast | $-22.30M | $-23.66M | $-25.84M | $-28.83M | $-28.29M | $-32.13M | $-29.96M | $-27.56M | $-37.36M | $-41.34M | $-47.32M | $-47.32M | $-54.83M | $-75.69M | $-86.64M | $-89.31M | $-107.68M | $-80.95M | $-47.71M | $-35.91M | $-72.94M | $35.60M | $-400.65M | $-31.95M | $-80.44M | $-28.77M | $-31.35M | $-29.67M | $-33.02M | $-12.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | 820.74% | - | -62.31% | 0.94% | 0.63% | - | 1.13% | 1.26% | 0.90% | 2.06% | 1.85% | 0.30% | 0.43% | 0.39% | 1.22% | 0.59% | 0.93% | 1.13% | 1.18% | 0.91% | 0.66% |
Inovio Pharmaceuticals's average Quarter net income forecast for Jun 23 is $-47.32M, with a range of $-47.32M to $-47.32M. INO's average Quarter net income forecast represents a -101.60% decrease compared to the company's last Quarter net income of $2.95B (Mar 23).
Inovio Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 | 19 |
| SG&A | - | - | - | - | - | - | - | - | - | $9.93B | - | $13.89M | $13.95M | $11.82M | - | $15.95M | $14.05M | $13.16M | $12.67M | $13.88M | $8.62M | $10.11M | $11.07M | $7.45M | $8.70M | $5.68M | $5.85M | $6.98M | $6.79M | $7.19M |
| Avg Forecast | $2.07M | $2.07M | $2.07M | $2.07M | $2.69M | $2.34M | $2.78M | $3.28M | $7.47M | $2.42M | $5.70M | $5.70M | $7.04M | $12.92M | $10.97M | $16.03M | $52.30M | $18.12M | $22.62M | $22.00M | $25.30M | $63.17M | $54.08M | $39.66M | $45.11M | $81.46M | $83.47M | $5.90M | $46.11M | $10.88M |
| High Forecast | $2.07M | $2.07M | $2.07M | $2.07M | $2.69M | $3.51M | $2.78M | $3.28M | $7.75M | $2.42M | $5.70M | $5.70M | $7.04M | $12.92M | $10.97M | $19.08M | $62.26M | $21.57M | $26.93M | $26.19M | $30.12M | $75.21M | $64.38M | $47.22M | $53.70M | $96.98M | $99.36M | $7.08M | $55.33M | $13.06M |
| Low Forecast | $2.07M | $2.07M | $2.07M | $2.07M | $2.69M | $1.17M | $2.78M | $3.28M | $7.18M | $2.42M | $5.70M | $5.70M | $7.04M | $12.92M | $10.97M | $11.45M | $37.36M | $12.94M | $16.16M | $15.71M | $18.07M | $45.12M | $38.63M | $28.33M | $32.22M | $58.19M | $59.62M | $4.72M | $36.89M | $8.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | 4102.01% | - | 2.44% | 1.98% | 0.91% | - | 1.00% | 0.27% | 0.73% | 0.56% | 0.63% | 0.34% | 0.16% | 0.20% | 0.19% | 0.19% | 0.07% | 0.07% | 1.18% | 0.15% | 0.66% |
Inovio Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $7.47M, based on 3 Wall Street analysts, with a range of $7.18M to $7.75M. The forecast indicates a -99.92% fall compared to INO last annual SG&A of $9.93B (Sep 23).
Inovio Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 | 19 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.13 | - | $11.41 | $-0.22 | $-0.16 | - | $-0.38 | $-0.52 | $-0.29 | $-0.39 | $-0.27 | $-0.11 | $0.31 | $-1.43 | $-0.41 | $-0.31 | $-0.22 | $-0.30 | $-0.30 | $-0.25 | $-0.09 |
| Avg Forecast | $-0.82 | $-0.87 | $-0.95 | $-1.06 | $-1.04 | $-1.14 | $-1.10 | $-1.01 | $-1.19 | $-1.52 | $-1.74 | $-1.74 | $-2.02 | $-3.50 | $-3.72 | $-4.13 | $-3.79 | $-3.88 | $-2.99 | $-2.23 | $-2.56 | $-2.22 | $-1.98 | $-2.66 | $-2.83 | $-3.03 | $-3.39 | $-3.08 | $-0.33 | $-0.33 |
| High Forecast | $-0.82 | $-0.87 | $-0.95 | $-1.06 | $-1.04 | $-1.07 | $-1.10 | $-1.01 | $-0.99 | $-1.52 | $-1.74 | $-1.74 | $-2.02 | $-3.50 | $-3.72 | $-2.59 | $-2.38 | $-2.44 | $-1.88 | $-1.40 | $-1.61 | $-1.40 | $-1.24 | $-1.67 | $-1.78 | $-1.91 | $-2.13 | $-1.94 | $-0.26 | $-0.27 |
| Low Forecast | $-0.82 | $-0.87 | $-0.95 | $-1.06 | $-1.04 | $-1.18 | $-1.10 | $-1.01 | $-1.37 | $-1.52 | $-1.74 | $-1.74 | $-2.02 | $-3.50 | $-3.72 | $-5.15 | $-4.72 | $-4.84 | $-3.73 | $-2.79 | $-3.20 | $-2.77 | $-2.47 | $-3.32 | $-3.53 | $-3.78 | $-4.23 | $-3.84 | $-0.40 | $-0.40 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.09% | - | -6.56% | 0.11% | 0.05% | - | 0.09% | 0.14% | 0.07% | 0.13% | 0.12% | 0.04% | -0.14% | 0.72% | 0.15% | 0.11% | 0.07% | 0.09% | 0.10% | 0.76% | 0.26% |
According to 1 Wall Street analysts, Inovio Pharmaceuticals's projected average Quarter EPS for Jun 23 is $-1.74, with a low estimate of $-1.74 and a high estimate of $-1.74. This represents a -115.25% decrease compared to INO previous annual EPS of $11.41 (Mar 23).
Inovio Pharmaceuticals Peer Comparison by Price Target
INO Forecast FAQ
Is Inovio Pharmaceuticals a good buy?
Yes, according to 4 Wall Street analysts, Inovio Pharmaceuticals (INO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 50.00% of INO's total ratings.
What is INO's price target?
Inovio Pharmaceuticals (INO) average price target is $22.67 with a range of $8 to $40, implying a 232.89% from its last price of $6.81. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Inovio Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for INO stock, the company can go up by 232.89% (from the last price of $6.81 to the average price target of $22.67), up by 487.37% based on the highest stock price target, and up by 17.47% based on the lowest stock price target.
Can Inovio Pharmaceuticals stock reach $10?
INO's average twelve months analyst stock price target of $22.67 supports the claim that Inovio Pharmaceuticals can reach $10 in the near future.
What are Inovio Pharmaceuticals's analysts' financial forecasts?
Inovio Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $534.7K (high $591.12K, low $478.28K), average EBITDA is $-535K (high $-478K, low $-591K), average net income is $-117M (high $-115M, low $-118M), average SG&A $11.09M (high $12.26M, low $9.92M), and average EPS is $-4.298 (high $-4.222, low $-4.336). INO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $400K (high $400K, low $400K), average EBITDA is $-400K (high $-400K, low $-400K), average net income is $-101M (high $-101M, low $-101M), average SG&A $8.3M (high $8.3M, low $8.3M), and average EPS is $-3.7 (high $-3.7, low $-3.7).
Did the INO's actual financial results beat the analysts' financial forecasts?
Based on Inovio Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $832.01M, beating the average analysts forecast of $1.03M by 80939.91%. Apple's EBITDA was $-144B, beating the average prediction of $-1.027M by 14020028.05%. The company's net income was $-135B, beating the average estimation of $-168M by 80209.59%. Apple's SG&A was $47.58B, beating the average forecast of $21.29M by 223373.33%. Lastly, the company's EPS was $-6.09, missing the average prediction of $-6.186 by -1.55%. In terms of the last quarterly report (Sep 2023), Inovio Pharmaceuticals's revenue was $388.45M, beating the average analysts' forecast of $116.67K by 332852.76%. The company's EBITDA was $-35.553B, beating the average prediction of $-117K by 30473823.22%. Inovio Pharmaceuticals's net income was $-33.93B, beating the average estimation of $-41.341M by 81973.83%. The company's SG&A was $9.93B, beating the average forecast of $2.42M by 410100.82%. Lastly, the company's EPS was $-0.13, missing the average prediction of $-1.52 by -91.45%